The story

The story

In 1932 Giuseppe Caraccia founded L.I.M. (Laboratorio Italiano Medicinali), which later became Bioindustria Farmaceutici Spa and today  Bioindustria L.I.M. SpA.

In 1932 Giuseppe Caraccia founded L.I.M. (Laboratorio Italiano Medicinali), which later became Bioindustria Farmaceutici Spa and today a Bioindustria L.I.M. SpA.

In 1940, the illustrious biologist Prof. Bice Neppi, one of the first women graduates in Italy, joined Bioindustria as lab director. She would lead in 1941 to the registration of a drug that was to be for 30 years the best-selling product of the company and would contribute to making it famous: the antianemic Emazian.

In 1945, the building in which the company is located was hit by Allied bombs and suffered considerable damage. At the end of the war the recovery was rapid and successful: the hepatic extract Emazian would be followed by many other opotherapy products and enzymes. A very efficient commercial network of high technical-scientific level was created.

In 1955 the company began to operate in the field of chemical synthesis. In the following years many molecules were developed that once again placed it as a leader in the Italian market. The most important research product realised is Neuraben, an antineuritic that is still widely used.

In 1987 a new plant for the production of synthetic raw materials (API) was opened, partly for internal use, and partly for sale to third parties in many countries of the world.

In 1995, the medicinal specialties were sold to the multinational Pfizer and the company specialized in the production of small-volume injectable generic drugs and large-volume infusion solutions (IV).

  • Bioindustria L.I.M. spa
  • Bioindustria L.I.M. spa